John Landry was named Chief Financial Officer of CVRx, Inc. As of November 6, 2026, CVRx, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from June 9, 2026 to September 21, 2026, naming 1 appointment and 1 departure (Form 8-K, September 21, 2026).
CVRx, Inc. named a new Chief Financial Officer on Sep 21. 30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like CVRx, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
CVRx, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-06-09 to 2026-09-21. They name 2 people, with 1 appointment and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as CVRx, Inc. files it.
Also on the record for CVRx, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| October 2, 2026 | Stake report, Schedule 13D/A, by Chernett Jorey | 0.62% of the class | 5%+ stakes | Source |
| August 24, 2026 | Stake report, Schedule 13D, by Chernett Jorey | 5.5% of the class | 5%+ stakes | Source |
| August 14, 2026 | Stake report, Schedule 13G, by Chernett Jorey | 5.5% of the class | 5%+ stakes | Source |
| January 12, 2026 | Stake report, Schedule 13G/A, by JOHNSON & JOHNSON | 15.4% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs CVRx, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on CVRx, Inc. and the records around it.
CVRx, Inc. elsewhere on the record
- 5%+ stake filings Oct 2026
- Who owns it
Companies that share a holder
- JOHNSON & JOHNSON also filed stake reports on 2 other companies: Rallybio Corporation (Apr 2026), Rapport Therapeutics, Inc. (Oct 2025)
- Chernett Jorey also filed stake reports on 16 other companies: WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026), KAZIA THERAPEUTICS LTD (Aug 2026)
Watch CVRx, Inc.
Get an email when CVRx, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on CVRx, Inc.?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on CVRx, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on CVRx, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-09-21 | In | Chief Financial Officer | 8-K, 2026-09-21 | ||
| 2026-06-09 | Out | Chief Financial Officer | 8-K, 2026-06-09 |
Who leads CVRx, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Chief Financial Officer: John Landry, appointed (filed 2026-09-21).
New leaders reset buying decisions — get the Full Report on CVRx, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Chief Financial Officer at CVRx, Inc., with the record behind each one.
Find candidates like Chief Financial Officer at CVRx, Inc.Every change, in the filing's words
Appointed: John Landry, Chief Financial Officer
On September 21, 2026, CVRx, Inc. (the "Company") announced that its Board of Directors (the "Board") appointed John Landry as Chief Financial Officer ("CFO").
- Mr. Landry succeeds Jared Oasheim who, as previously disclosed on June 8, 2026, gave notice of his intention to resign as CFO after his successor commences in the role.
- Mr. Landry's employment will commence on October 12, 2026 to facilitate a smooth transition before assuming the responsibilities of CFO on the day after the Company files its Form 10-Q for its quarter ending September 30, 2026.
- Mr. Landry, age 54, currently serves as Chief Financial Officer of Nyxoah SA, a medical technology company focused on the development and commercialization of innovative solutions to treat obstructive sleep apnea, a position he has held since November 2024.
- Mr. Landry previously served as Senior Vice President, Chief Financial Officer, and Treasurer of Vapotherm Inc., a developer and manufacturer of advanced respiratory technology, from July 2020 to October 2024, prior to which he served as Vice President, Chief Financial Officer, Secretary and Treasurer from August 2012 to July 2020.
- Prior to Vapotherm, Mr. Landry served as Director of International Marketing at Medtronic, Inc. from 2011 to 2012 following its acquisition in August 2011 of Salient Surgical Technologies, Inc., where Mr. Landry held positions of increasing responsibility from 2004 to 2011.
Departing: Jared Oasheim, Chief Financial Officer
On June 7, 2026, Jared Oasheim, the Chief Financial Officer ("CFO") of CVRx, Inc. (the "Company"), gave notice of his intention to resign from the Company to pursue other professional opportunities.
- Mr. Oasheim will remain CFO and continue serving as the principal accounting officer until his successor commences in the role and he will remain employed full-time with his current base salary until the later of August 31, 2026 or 30 days after the CFO transition.
- Subsequently, he will be available as a consultant through February 2027, compensated at an hourly rate of $245 per hour.
- The Company is initiating a search to identify a successor CFO.
Tools for this story
Each opens in a new tab, filled in for CVRx, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.